948 related articles for article (PubMed ID: 26450217)
1. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
Triplitt C; Solis-Herrera C
Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Nauck MA; Quast DR; Wefers J; Meier JJ
Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
[TBL] [Abstract][Full Text] [Related]
4. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
Chun JH; Butts A
JAAPA; 2020 Aug; 33(S8 Suppl 1):3-18. PubMed ID: 32756220
[TBL] [Abstract][Full Text] [Related]
5. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.
Meece J
Adv Ther; 2017 Mar; 34(3):638-657. PubMed ID: 28210986
[TBL] [Abstract][Full Text] [Related]
6. Long-acting GLP-1RAs: An overview of efficacy, safety, and their role in type 2 diabetes management.
Chun JH; Butts A
JAAPA; 2020 Aug; 33(8):3-18. PubMed ID: 32740121
[TBL] [Abstract][Full Text] [Related]
7. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
Madsbad S; Kielgast U; Asmar M; Deacon CF; Torekov SS; Holst JJ
Diabetes Obes Metab; 2011 May; 13(5):394-407. PubMed ID: 21208359
[TBL] [Abstract][Full Text] [Related]
8. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
Kuwata H; Yabe D; Murotani K; Fujiwara Y; Haraguchi T; Kubota S; Kubota-Okamoto S; Usui R; Ishitobi M; Yamazaki Y; Hamamoto Y; Kurose T; Seino Y; Yamada Y; Seino Y
J Diabetes Investig; 2021 Dec; 12(12):2162-2171. PubMed ID: 34022121
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials.
Xue X; Ren Z; Zhang A; Yang Q; Zhang W; Liu F
Int J Clin Pract; 2016 Aug; 70(8):649-56. PubMed ID: 27456750
[TBL] [Abstract][Full Text] [Related]
10. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
Thompson AM; Trujillo JM
Ann Pharmacother; 2015 Mar; 49(3):351-9. PubMed ID: 25565404
[TBL] [Abstract][Full Text] [Related]
11. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
Madsbad S
Diabetes Obes Metab; 2016 Apr; 18(4):317-32. PubMed ID: 26511102
[TBL] [Abstract][Full Text] [Related]
12. Is insulin the most effective injectable antihyperglycaemic therapy?
Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
14. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
Shaefer CF; Kushner P; Aguilar R
Postgrad Med; 2015; 127(8):818-26. PubMed ID: 26371721
[TBL] [Abstract][Full Text] [Related]
15. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
Guo XH
Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
[TBL] [Abstract][Full Text] [Related]
16. A Plethora of GLP-1 Agonists: Decisions About What to Use and When.
Samson SL; Garber AJ
Curr Diab Rep; 2016 Dec; 16(12):120. PubMed ID: 27766579
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology of glucagon-like peptide-1 receptor agonists.
Sfairopoulos D; Liatis S; Tigas S; Liberopoulos E
Hormones (Athens); 2018 Sep; 17(3):333-350. PubMed ID: 29949126
[TBL] [Abstract][Full Text] [Related]
18. Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.
Singhal M; Unni S; Schauerhamer M; Nguyen H; Hurd J; McAdam-Marx C
J Manag Care Spec Pharm; 2017 Mar; 23(3):267-275. PubMed ID: 28230449
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella R; Pechtner V; Corcos A; Consoli A
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
[TBL] [Abstract][Full Text] [Related]
20. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
Urquhart S; Willis S
JAAPA; 2020 Aug; 33(8):19-30. PubMed ID: 32740122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
